EuPA Open Proteomics (Jun 2016)

Proprotein convertase 1/3 inhibited macrophages: A novel therapeutic based on drone macrophages

  • Marie Duhamel,
  • Franck Rodet,
  • Adriana Murgoci,
  • Maxence Wisztorski,
  • Robert Day,
  • Isabelle Fournier,
  • Michel Salzet

DOI
https://doi.org/10.1016/j.euprot.2016.03.003
Journal volume & issue
Vol. 11, no. C
pp. 20 – 22

Abstract

Read online

We demonstrated here thanks to proteomic, that proprotein convertase 1/3 knockdown macrophages present all the characteristic of activated pro-inflammatory macrophages. TLR4 and TLR9 signaling pathways can be enhanced leading to the secretion of pro-inflammatory factors and antitumor factors. We can control their activation by controlling one enzyme, PC1/3. In a tumor context, PC1/3 inhibition in macrophages may reactivate them and lead to a cytokine storm after stimulation “at distance” with a TLR ligand. Therefore, we name these proprotein convertase inhibited macrophages the “drone macrophages”. They constitute an innovative cell therapy to treat efficiently tumors.